Background
Methods
Participants and criteria
Data source
Variables and statistics
Results
Demographics and clinical characteristics of the 605 eligible patients before PSM
Characteristic | Variable | Before PSM | ||
---|---|---|---|---|
No-PBT | PBT |
P value | ||
(n = 512) | (n = 93) | |||
Age | Y ± SD | 57.42 ± 10.815 | 56.54 ± 11.801 | 0.176a
|
Gender | female/ male | 190/322 | 48/45 | 0.008c
|
Preoperative Hb | g/L ± SD | 132.53 ± 16.22 | 118.63 ± 17.68 | 0.329a
|
Platelet | 1 × 109/L ± SD | 179.25 ± 64.02 | 201.30 ± 97.35 | 0.038a
|
Total bilirubin | available data | 510(99.61%) | 92 (98.92%) | |
umol /L ± SD | 24.98 ± 55.35 | 86.79 ± 134.47 | <0.001b
| |
AST | available data | 502(98.05%) | 90 (96.77%) | |
U/L ± SD | 44.56 ± 87.09 | 56.21 ± 57.45 | <0.001b
| |
ALT | available data | 509 (99.41%) | 92 (98.92%) | |
U/L ± SD | 50.40 ± 95.22 | 57.90 ± 67.28 | 0.002b
| |
AFP | available data | 497 (97.07%) | 91 (97.85%) | |
ng/mL ± SD | 95.28 ± 953.72 | 93.02 ± 585.95 | 0.982b
| |
CEA | available data | 489 (95.51%) | 87 (93.55%) | |
ng/mL ± SD | 22.42 ± 154.07 | 61.84 ± 330.14 | 0.060b
| |
CA19–9 | available data | 486 (94.92%) | 86 (92.47%) | |
U/mL ± SD | 1152.16 ± 3116.14 | 2698.09 ± 4923.75 | <0.001b
| |
PT | available data | 506 (98.83%) | 91 (97.85%) | |
s ± SD | 11.20 ± 9.23 | 11.87 ± 3.11 | 0.093b
| |
INR | available data | 502 (98.05%) | 89 (95.70%) | |
Value ±SD | 0.98 ± 0.11 | 0.98 ± 0.14 | 0.910b
| |
HBsAg | available data | 506 (98.83%) | 93 (100.00%) | |
(−)/(+) | 302/204 | 71/22 | 0.002c
| |
Anti-HCV | available data | 502 (98.05%) | 93 (100.00%) | |
(−)/(+) | 493/9 | 91/2 | 0.814c
| |
Tumor number | available data | 511 (99.80%) | 92 (98.92%) | |
1/>1 | 426/85 | 81/11 | 0.259c
| |
TMD | available data | 509 (99.41%) | 93 (100.00%) | |
cm | 6.48 ± 3.16 | 6.92 ± 3.44 | 0.284b
| |
TNM stage | available data | 489 (95.51%) | 74 (79.57%) | |
I/II/III/IVa | 294/80/17/98 | 47/15/0/12 | 0.433c
| |
Cirrhotic nodule | available data | 512 (100.00%) | 91 (97.85%) | |
no/ yes | 344/168 | 70/21 | 0.065c
| |
DD | available data | 412 (80.47%) | 76 (81.72%) | |
I/II-III/IV | 2/408/2 (0.49%) | 0/76/0 (0.00%) | 1.000c
| |
IBL | available data | 503 (98.24%) | 93 (100.00%) | |
<1 L/≥1 L | 499/4 (99.20%) | 61/32 (65.59%) | <0.001c
| |
Preventive TACE | no/yes | 474/38 (92.58%) | 86/7 (92.47%) | 0.972c
|
Propensity Score | available data | 501 (84.49%) | 92 (15.51%) | |
0.096 ± 0.104 | 0.479 ± 0.372 | <0.001b
|
Confounding factors between the PBT groups and outcome
Characteristic | Variables | Before PSM | |||||||
---|---|---|---|---|---|---|---|---|---|
Univariate (OS, COX Regression) | Univariate (DFS, COX Regression) | Univariate (Logistic Regression) | Multivariate (Logistic Regression) | ||||||
HR (95% CI) |
P valuea
| HR (95% CI) |
P valuea
| OR (95% CI) |
P valuea
| OR (95% CI) |
P valuea
| ||
Age | Y ± SD | 1.007 (0.998–1.017) | 0.131 | 1.006 (0.997–1.014) | 0.219 | 0.993 (0.973–1.013) | 0.477 | ||
Gender | female | reference | 0.121 | reference | 0.145 | reference | 0.009 | reference | 0.506 |
male | 1.184 (0.956–1.466) | 1.163 (0.949–1.425) | 0.553 (0.355–0.863) | 0.790 (0.393–1.585) | |||||
Preoperative Hb | g/L ± SD | 0.988 (0.981–0.994) | <0.001 | 0.990 (0.985–0.996) | 0.001 | 0.951 (0.937–0.965) | <0.001 | 0.947 (0.927–0.967) | <0.001 |
Platelet | 1 × 109/L ± SD | 1.001 (1.000–1.003) | 0.177 | 1.001 (0.999–1.002) | 0.222 | 1.004 (1.001–1.007) | 0.006 | 1.001 (0.997–1.006) | 0.537 |
Total bilirubin | umol/L + SD | 1.003 (1.002–1.004) | <0.001 | 1.002(1.001–1.003) | 0.001 | 1.007 (1.005–1.010) | <0.001 | 1.006 (1.003–1.009) | <0.001 |
AST | U/L ± SD | 1.000 (0.999–1.002) | 0.487 | 1.001 (1.000–1.002) | 0.205 | 1.001 (0.999–1.003) | 0.24 | ||
ALT | U/L ± SD | 1.001 (1.000–1.002) | 0.029 | 1.001 (1.000–1.002) | 0.049 | 1.001 (0.999–1.003) | 0.472 | ||
AFP | ng/mL ± SD | 1.000 (1.000–1.000) | 0.379 | 1.000 (1.000–1.000) | 0.451 | 1.000 (1.000–1.000) | 0.983 | ||
CEA | ng/mL ± SD | 1.000 (1.000–1.000) | 0.745 | 1.001 (1.000–1.001) | 0.01 | 1.001 (1.000–1.002) | 0.108 | ||
CA19–9 | U/mL ± SD | 1.000 (1.000–1.000) | <0.001 | 1.000 (1.000–1.000) | <0.001 | 1.000 (1.000–1.000) | <0.001 | 1.000 (1.000–1.000) | 0.903 |
PT | s ± SD | 1.000 (0.988–1.012) | 0.99 | 1.008 (0.994–1.022) | 0.28 | 1.007 (0.986–1.028) | 0.507 | ||
INR | Value ±SD | 2.307 (0.949–5.605) | 0.065 | 1.692 (0.742–3.855) | 0.211 | 0.714 (0.095–5.388) | 0.744 | ||
HBsAg | (−) | reference | 0.401 | reference | 0.232 | reference | 0.003 | reference | 0.126 |
(+) | 0.912 (0.737–1.130) | 0.882 (0.718–1.084) | 0.459 (0.275–0.764) | 0.552 (0.258–1.183) | |||||
Anti-HCV | (−) | reference | 0.04 | reference | 0.076 | reference | 0.814 | ||
(+) | 0.395 (0.163–0.956) | 0.507 (0.240–1.073) | 1.204 (0.256–5.663) | ||||||
Tumor number | 1 | reference | 0.446 | reference | 0.559 | reference | 0.261 | ||
>1 | 1.122 (0.835–1.507) | 1.088 (0.821–1.441) | 0.681 (0.348–1.332) | ||||||
TMD | cm | 1.052 (1.017–1.087) | 0.003 | 1.057 (1.025–1.090) | <0.001 | 1.041 (0.975–1.113) | 0.229 | ||
TNM stage | I | reference | <0.001 | reference | 0.001 | reference | 0.784 | ||
II | 1.105 (0.804–1.518) | 1.192 (0.882–1.611) | 1.173 (0.624–2.206) | ||||||
III | 2.167 (1.104–4.255) | 1.823 (0.961–3.455) | 0.000(0.000-.) | ||||||
IVa | 2.088 (1.592–2.739) | 1.657 (1.273–2.157) | 0.766 (0.390–1.503) | ||||||
Cirrhotic nodule | no | reference | 0.274 | reference | 0.799 | reference | 0.067 | ||
yes | 1.127 (0.910–1.397) | 1.028 (0.834–1.266) | 0.614 (0.365–1.035) | ||||||
DD | I | reference | 0.982 | reference | 0.997 | reference | 1.000 | ||
II-III | 2997.401 (0.000-.) | 8142.694 (0.000-.) | 300,921,742.177 (0.000-.) | ||||||
IV | 2632.881 (0.000-.) | 8450.077 (0.000-.) | 1.000 (0.000-.) | ||||||
IBL | <1000 mL | reference | 0.005 | reference | 0.002 | reference | <0.001 | reference | <0.001 |
≥1000 mL | 1.733 (1.184–2.535) | 1.816 (1.243–2.652) | 65.443 (22.383–191.341) | 168.205 (43.249–654.184) | |||||
Preventive TACE | no | reference | 0.349 | reference | 0.144 | reference | 0.972 | ||
yes | 0.841 (0.585–1.209) | 1.300 (0.914–1.848) | 1.015 (0.439–2.348) |
Demographics and clinical characteristics of 215 matched patients after PSM
Characteristic | Variable | After PSM | ||
---|---|---|---|---|
No-PBT | PBT |
P value | ||
(n = 163) | (n = 52) | |||
Age | Y ± SD | 57.67 ± 10.77 | 56.90 ± 12.34 | 0.114a
|
Gender | female/male | 72/91 | 27/25 | 0.330c
|
Preoperative Hb | g/L ± SD | 125.38 ± 15.90 | 120.25 ± 18.72 | 0.232a
|
Platelet | 1 × 109/L ± SD | 180.29 ± 65.50 | 193.38 ± 93.35 | 0.350a
|
Total bilirubin | umol/L ± SD | 31.34 ± 62.77 | 60.36 ± 115.37 | 0.070b
|
AST | available data | 161 (98.77%) | 50 (96.15%) | |
U/L ± SD | 46.25 ± 81.74 | 47.92 ± 62.24 | 0.763b
| |
ALT | U/L ± SD | 51.14 ± 80.64 | 53.35 ± 77.74 | 0.374b
|
AFP | available data | 158 (96.93%) | 52 (100.00%) | |
ng/mL ± SD | 196.77 ± 1590.50 | 123.49 ± 741.51 | 0.994b
| |
CEA | available data | 157 (96.32%) | 49 (94.23%) | |
ng/mL ± SD | 22.66 ± 149.81 | 95.03 ± 437.78 | 0.375b
| |
CA19–9 | available data | 156 (95.71%) | 48 (92.31%) | |
U/mL ± SD | 1170.62 ± 3041.71 | 1491.47 ± 3691.9 | 0.439b
| |
PT | available data | 161 (98.77%) | 51 (98.08%) | |
s ± SD | 10.76 ± 4.65 | 11.96 ± 3.59 | 0.075b
| |
INR | available data | 158 (96.93%) | 50 (96.15%) | |
Value ±SD | 0.98 ± 0.13 | 0.98 ± 0.15 | 0.997b
| |
HBsAg | available data | 160 (98.16%) | 52 (100.00%) | |
(−)/(+) | 100/60 | 39/13 | 0.100c
| |
Anti-HCV | available data | 159 (97.55%) | 52 (100.00%) | |
(−)/(+) | 157/2 | 51/1 | 0.726c
| |
Tumor number | 1/>1 | 140/23 | 43/9 | 0.574c
|
TMD | cm | 6.84 ± 3.39 | 6.83 ± 3.38 | 0.967c
|
TNM stage | available data | 155(95.09%) | 44 (84.62%) | |
I/II/III/IVa | 92/24/5/34 | 25/11/0/8 | 0.968c
| |
Cirrhotic nodule | available data | 163 (100%) | 50 (96.2%) | |
no/yes | 112/51 | 40/10 | 0.123c
| |
DD | available data | 126 (77.30%) | 43 (82.70%) | |
I/ II-III | 2/124 (1.59%) | 0/43 (0.00%) | 0.407c
| |
IBL | <1 L/≥1 L | 161/2 (98.77%) | 52/0 (100.00%) | 0.423c
|
Preventive TACE | no/yes | 153/10 (93.87%) | 47/5 (90.38%) | 0.392c
|
Propensity Score | 0.136 ± 0.117 | 0.193 ± 0.167 | 0.785d
|
Perioperative blood transfusion has no effect on OS and DFS after PSM
Characteristic | Variable | Before PSM | After PSM | ||||
---|---|---|---|---|---|---|---|
univariate | multivariate | univariate | |||||
HR (95% CI) |
P valuea
| HR (95% CI) |
P valuea
| HR (95% CI) |
P valuea
| ||
PBT(OS) | no | reference | <0.001 | reference | 0.479 | reference | 0.070 |
yes | 1.889 (1.446–2.468) | 1.172 (0.756–1.816) | 1.429 (0.972–2.103) | ||||
PBT(DFS) | no | reference | 0.001 | reference | 0.799 | reference | 0.238 |
yes | 1.589 (1.221–2.067) | 0.944 (0.608–1.466) | 1.262 (0.858–1.856) |